Alector, Inc.
Clinical-stage biotech using immuno-neurology to treat neurodegenerative diseases.
ALEC | US
Overview
Corporate Details
- ISIN(s):
- US0144421072
- LEI:
- Country:
- United States of America
- Address:
- 131 OYSTER POINT BLVD., SUITE 600, 94080 SOUTH SAN FRANCISCO
- Website:
- https://alector.com
- Sector:
- Manufacturing
Description
Alector, Inc. is a clinical-stage biotechnology company that develops therapies for neurodegenerative diseases. The company pioneers an approach known as immuno-neurology, which utilizes the body's immune system to address brain disorders. By integrating insights from human genetics, neuroscience, and immunology, Alector is advancing a pipeline of potential first-in-class and best-in-class medicines. Its therapeutic candidates are designed to treat conditions such as Alzheimer's disease and frontotemporal dementia by removing toxic proteins, replacing deficient proteins, and restoring the function of immune and nerve cells. The company's primary mission is to slow the progression of neurodegenerative diseases and improve overall brain health.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Alector, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Alector, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Alector, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
